DISH Network (NASDAQ: DISH ) will not raise its bid to buy Sprint Nextel (NYSE: S ) after SoftBank's most recent counteroffer to the satellite TV provider's proposal, DISH announced late yesterday.
Instead, DISH said it would concentrate on acquiring Clearwire, the network provider that Sprint is also bidding on. DISH said in a statement:
While DISH continues to see strategic value in a merger with Sprint, the decisions made by Sprint to prematurely terminate our due diligence process and accept extreme deal protections in its revised agreement with SoftBank, among other things, have made it impracticable for DISH to submit a revised offer by the June 18th deadline imposed by Sprint. We will consider our options with respect to Sprint, and focus our efforts and resources on completing the Clearwire tender offer.
Japanese telecom SoftBank's original agreement with Sprint called for $20.1 billion to acquire 70% of the No. 3 U.S. carrier. DISH's counteroffer of $25.5 billion for Sprint seemed to be enough to sway shareholders to vote down the SoftBank deal. However, SoftBank's new agreement with Sprint calls for an additional $4.5 billion in cash for Sprint stockholders, and that has effectively undercut DISH's efforts.
Best Services Companies To Invest In Right Now: ASB Bancorp Inc (ASBB)
ASB Bancorp, Inc. (ASB Bancorp), incorporated in May 2011, focuses to become the holding company for Asheville Savings Bank, S.S.B. (Asheville Savings Bank). ASB Bancorp, Inc.�� business activity will be the ownership of the Asheville Savings Bank. Asheville Savings Bank is a chartered savings bank. It operates as a community-oriented financial institution offering traditional financial services to consumers and businesses in its market area. It attracts deposits from the general public and use those funds to originate one-to four-family residential mortgage loans and commercial real estate loans, and home equity loans and lines of credit, consumer loans, construction and land development loans, and commercial and industrial loans. It conducts its lending and deposit activities with individuals and small businesses in its primary market area. Its market area is Asheville, North Carolina and the rest of Buncombe County where it has eight branch offices, as well as Henderson, Madison, McDowell and Transylvania Counties where it has five branch offices.
Lending Activities
Asheville Savings Bank loan portfolio include real estate mortgage loans, including one- to four-family residential mortgage loans and commercial mortgage loans, and revolving mortgage loans, which consist of home equity loans and lines of credit, consumer loans, construction and land development loans, and commercial and industrial loans. As of March 31, 2011, it had $177.8 million in one- to four-family residential loans, which represented 36.7% of its total loan portfolio. Its origination of residential mortgage loans enables borrowers to purchase or refinance existing homes located in its primary market area. It offers a mix of adjustable rate mortgage loans and fixed-rate mortgage loans with terms of up to 30 years.
Asheville Savings Bank offers fixed- and adjustable-rate mortgage loans secured by non-residential real estate and multi-family properties. As of March 31, 2011, commercial mort! gage loans totaled $162.7 million, or 33.5% of its total loan portfolio. Its commercial mortgage loans are secured by commercial, industrial and manufacturing, small to moderately-sized office and retail properties, hotels, multi-family properties and hospitals and churches located in its primary market area. As of March 31, 2011, $35.6 million or 21.9% of its commercial real estate loans were secured by owner-occupied properties. It originates fixed-rate and adjustable-rate commercial mortgage loans, generally with terms of three to five years and payments based on an amortization schedule of up to 25 years. It has originated construction and land development loans for commercial properties, such as retail shops and office units, and multi-family properties, and construction and land development loans for one-to four-family homes. As of March 31, 2011, commercial construction and land development loans totaled $27.8 million, which represented 5.7% of its total loan portfolio, and residential construction and land development loans totaled $7.9 million, which represented 1.6% of its total loan portfolio. As of March 31, 2011, it had speculative residential construction loans of $3.1 million and speculative commercial construction loans of $9.6 million.
Asheville Savings Bank offers revolving mortgage loans, which consist of home equity loans and lines of credit, and various consumer loans, including automobile loans and loans secured by deposits. As of March 31, 2011, revolving mortgage loans totaled $52 million, or 10.7% of its total loan portfolio, and consumer loans totaled $41.1 million, or 8.5% of its total loan portfolio. Its revolving mortgage loans consist of both home equity loans with fixed-rate amortizing term loans with terms of up to 15 years and adjustable rate lines of credit with interest rates indexed to the prime rate.
Asheville Savings Bank offers commercial and industrial loans to small businesses located in its primary market area. As of March 31, 2011, co! mmercial ! and industrial loans totaled $15.8 million, which represented 3.2% of its total loan portfolio. Its commercial and industrial loan portfolio consists of loans, which are secured by equipment, accounts receivable and inventory, but also includes a smaller amount of unsecured loans for purposes of financing expansion or providing working capital for general business purposes.
Investment Activities
As of March 31, 2011, Asheville Savings Bank�� investment portfolio consisted of the United States government and agency securities, mortgage-backed securities and securities issued by government sponsored enterprises, and municipal securities. As of March 31, 2011, its securities portfolio represented 27.2% of total assets. As of March 31, 2011, $198.6 million of its securities portfolio was classified as available for sale and $5.7 million of its securities portfolio was classified as held to maturity. Securities classified as held to maturity are United States government sponsored securities, mortgage-backed securities and state and local government securities. As of March 31, 2011, it had four million dollars of other investments, at cost, which consisted of Federal Home Loan Bank of Atlanta.
Sources of Funds
Deposits, borrowings and loan repayments are the sources of Asheville Savings Bank funds for lending and other investment purposes. It uses advances from the Federal Home Loan Bank of Atlanta to supplement its investable funds. The Federal Home Loan Bank functions as a central reserve bank providing credit for member financial institutions. Advances are made under several different programs, each having its own interest rate and range of maturities. It also utilizes securities sold under agreements to repurchase and overnight repurchase agreements to supplement its supply of investable funds and to meet deposit withdrawal requirements.
Subsidiaries
Asheville Savings Bank has two subsidiaries, Appalachian Financial Services,! Inc., wh! ich was formed to engage in investment activities, and Wenoca, Inc., which serves as Asheville Savings Bank�� trustee regarding deeds of trust. Both subsidiaries are organized as North Carolina corporations.
Advisors' Opinion:- [By Tim Melvin]
ASB Bancorp (ASBB) is the holding company for Ashville in western North Carolina. The bank has 13 branches and total assets of around $733 million. Nonperforming assets are just 2.1% of total assets and the bank is massively over-reserved for future losses, with loan reserves at 6 times nonperforming loans. The bank bought back 544,494 shares of common stock at an average price of $16.79 per share in 2013. The board just authorized a new 5% buyback in January 2014. The stock is trading around 80% of book value, so management is buying the shares on the cheap — and that should bode well for shareholders in the future.
Top Japanese Companies For 2014: TESARO Inc (TSRO)
TESARO, Inc. (TESARO), incorporated in March 2010, is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�� marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells.
Rolapitant
Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). It is in Phase III clinical trials. CINV, if not prevented by prophylaxis, has the potential to afflict up to 90% or more of cancer patients undergoing chemotherapy, depending upon the type of chemotherapy administered the dosing schedule of the chemotherapy, and the patients' age and gender, among other predisposing factors. Prolonged nausea and vomiting may result in unwanted weight loss, dehydration and malnutrition, as well as hospitalization. The Company has in-licensed the rights to rolapitant from OPKO Health, Inc.
TSR-011
TSR-011 is an orally available ALK inhibitor in preclinical development. ALK is known to be involved in certain types of cancers, including subsets of NSCLC, neuroblastoma and lymphoma. For patients in these subsets, the ALK gene is fused to an activating partner or contains point mutations, resulting in constitutive activation of ALK and the growth of cancer cells and tumor development. Inhibition of ALK in these cancer cells results in cell death and tumor growth inhibition or regression. In August 2011, the United States Food and Drug Administration approved the first ALK inhibitor, developed by Pfizer Inc., Xalkori (crizotinib), which was approved for the treatment of patients with locally advanced or metastatic NSCLC that are ALK positive.
The Company competes with GlaxoSmithKline plc, Roche Holding Ltd! . and Sanofi S.A.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
Tesaro (NASDAQ: TSRO) shares shot up 18.28 percent to $28.40 after the company reported successful primary and secondary endpoints in final Phase 3 trial for rolapitant. - [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company TESARO (NASDAQ: TSRO ) has received the dreaded one-star ranking.
Top Japanese Companies For 2014: Vical Incorporated(VICL)
Vical Incorporated engages in the research and development of biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its products include Allovectin, a Phase III clinical trial product to treat metastatic melanoma; CyMVectin prophylactic vaccine for cytomegalovirus, which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic and prophylactic vaccines for herpes simplex type 2 virus, which is under preclinical trial to prevent and protect against recurring flare-ups, reduce viral shedding ,and transmission. The company, through corporate collaborations, develops TransVax, which is in Phase III clinical trials to protect against CMV infection after stem cell transplants, as well as in Phase II clinical trial to protect against CMV infection after solid organ transplants; Collategene, an angiogenic therapy enc oding hepatocyte growth factor that is in Phase III clinical trials to induce local growth of blood vessels to restore blood flow to limbs affected by critical limb ischemia; Apex-IHN prophylactic vaccine for infectious hematopoietic necrosis virus for the prevention of infection and disease in farm-raised salmon when exposed to infected wild salmon ; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to increase survival time of dogs with oral melanoma. Vical Incorporated, through government collaboration, develops Prophylactic and/or therapeutic HIV vaccine, a Phase IIb clinical trial product to prevent/treat infection, disease, and/or viral shedding; and Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all 4 dengue serotypes. The company was founded in 1987 and is based in San Diego, California.
Advisors' Opinion:- [By Rich Bieglmeier]
[Related -Vical (VICL) Licenses Vaxfectin Adjuvant For Use In Malaria Vaccines To Cyvax]
Vical researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases.
- [By Roberto Pedone]
Another stock that's starting to trend within range of triggering a major breakout trade is Vical (VICL), which engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. This stock has been hit hard by the sellers over the last six months, with shares off sharply by 65%.
If you look at the chart for Vical, you'll notice that this stock has been trending sideways and consolidating over the last two months, with shares moving between $1.01 on the downside and $1.35 on the upside. Shares of VICL have started to uptrend over the last few weeks, with shares moving higher from its low of $1.01 to its recent high of $1.35 a share. During that move, shares of VICL have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now taken shares of VICL back above its 50-day moving average of $1.16 share and it's quickly pushing the stock within range of triggering a major breakout trade.
Traders should now look for long-biased trades in VICL if it manages to break out above some near-term overhead resistance at $1.35 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.17 million shares. If that breakout hits soon, then VICL will set up to re-test or possibly take out its next major overhead resistance level at $1.53 a share to its gap-down day high of $1.61 a share. Any high-volume move above those levels will then give VICL a chance to re-fill some of its previous gap-down-day zone from last August that started at $3.70 a share.
Traders can look to buy VICL off any weakness to anticipate that breakout and simply use a stop that sits just below its 50-day moving average at $1.20 a share or near more support at $1.10 a share. One can also buy VICL off strength once it starts to cle
Top Japanese Companies For 2014: Theragenics Corporation(TGX)
Theragenics Corporation operates as a medical device company serving the cancer treatment and surgical products markets primarily in the United States and Europe. It operates through two segments, Surgical Products and Brachytherapy Seed. The Surgical Products segment manufactures, markets, and sells disposable devices primarily utilized in surgical procedures. It offers wound closure products, including sutures, needles, and other surgical products; vascular access products comprising introducer sheaths, guidewires, and accessories; and specialty needles consisting of coaxial, biopsy, brachytherapy, guidewire introducer, spinal, and disposable veress, as well as access trocars and other needle-based products. This segment?s products are used in various markets and applications, such as interventional cardiology and radiology, vascular surgery, orthopedics, plastic surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. The Brachytherapy See d segment manufactures, markets, and sells TheraSeed and I-Seed, which are FDA-cleared devices for treatment of solid localized tumors and localized prostate cancer. The company sells its products primarily to physicians, hospitals and other healthcare providers, original equipment manufacturers, and to a network of distributors. Theragenics Corporation was founded in 1981 and is based in Buford, Georgia.
Advisors' Opinion:- [By James E. Brumley]
I hate to be the one to say I told you so, but, I told you so. Back on February 26th I suggested IsoRay, Inc. (NYSEMKT:ISR) shares were a budding breakout play. The 48% rally that's played out for ISR in the meantime unfurled right on cue. While overbought in the very short run, this small cap stock looks like it's earning the right to be compared to the likes of bigger brothers in the cancer-treatment space... names like Roche Holding Ltd. (OTCMKTS:RHHBY) or Theragenics Corporation (NYSE:TGX).
No comments:
Post a Comment